Sugi Predict

Sugi Predict / Compounds / SCHEMBL530919

SCHEMBL530919

SCHEMBL530919

O=Cc1cc(Cl)c(O)cc1O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 9/20 0.54
▸ HPGD P15428 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TYR P14679 2/20 0.39
▸ TRIM24 O15164 2/20 0.39
▸ TRIM33 Q9UPN9 2/20 0.39
▸ CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29044277 1.00 ERN1 (0.54) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL29444246 1.00 ERN1 (0.54) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL25240603 0.91 ERN1 (0.59) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL1922524 0.88 ERN1 (0.61) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL31442964 0.88 ERN1 (0.61) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL3377931 0.86 ERN1 (0.54) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL17660183 0.82 ERN1 (0.52) ERN1TYRTRIM24TRIM33CDK1
SCHEMBL692164 0.80 ERN1 (0.48) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL18728358 0.80 ERN1 (0.44) ERN1HPGDTSHRHSD17B10TDP1
SCHEMBL22492694 0.80 ERN1 (0.50) ERN1HPGDTSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113264967-B Programmed death ligand-1 targeted compound and preparation method and application thereof 江苏省原子医学研究所 2023-04-18 — — CN claimed
CN-114573563-A Bifunctional molecular compound for inducing PD-L1 protein degradation and preparation and application thereof 沈阳药科大学 2022-06-03 — — CN claimed
CN-112028916-B Programmed cell death protein receptor-1 targeted molecular probe and preparation 江苏省原子医学研究所 2022-04-26 — — CN claimed
CN-113264967-A Programmed death ligand-1 targeted compound and preparation method and application thereof 江苏省原子医学研究所 2021-08-17 — — CN claimed
CN-112876411-A Compound and application thereof in synthesis of PDL1 antagonist drug molecules 杭州阿诺生物医药科技有限公司 2021-06-01 — — CN claimed
CN-112028916-A Programmed cell death protein receptor-1 targeted molecular probe and preparation 江苏省原子医学研究所 2020-12-04 — — CN claimed
CN-110256283-A A kind of caffeic acid acyl hydrazone derivative and the preparation method and application thereof 南京神奇科技开发有限公司 2019-09-20 — — CN claimed
CN-104525265-B 2,4-dihydroxy-5-Chlorobenzaldehyde contracting aminoacid copper complex catalyst, preparation method and application 聊城大学 2017-01-04 — — CN claimed
CN-104525265-A 2,4-dihydroxy-5-chlorobenzaldehyde amino acid copper complex catalyst, and preparation method and application thereof UNIV LIAOCHENG 2015-04-22 — — CN claimed
US-12624022-B2 Heterocyclic immunomodulators as PDL1 checkpoint inhibitor Janssen Sciences Ireland Unlimited Company (IE) 2026-05-12 — — US disclosed
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
EP-4698520-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF Gandeeva Therapeutics, Inc. (US) 2026-02-25 — — EP disclosed
US-12466822-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2025-11-11 — — US disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 — — US disclosed
EP-0817785-A2 SUBSTRATES FOR BETA-LACTAMASE AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-01-14 — — EP disclosed
WO-1997048820-A1 PROMISCUOUS G-PROTEIN COMPOSITIONS AND THEIR USE AURORA BIOSCIENCES CORPORATION (US) 1997-12-24 — — WO disclosed
US-5677342-A ANTIDIABETIC AGENT AMERICAN HOME PRODUCTS CORPORATION (US) 1997-10-14 — — US disclosed
WO-1997008126-A1 PHENOXY ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS AND ANTIHYPERGLYCEMIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1997-03-06 — — WO disclosed
WO-1996041166-A2 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-12-19 — — WO disclosed
WO-1996030540-A2 SUBSTRATES FOR BETA-LACTAMASE AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 ERN1 3910/4885HPGD 2323/4885TSHR 573/4885
US-12466822-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS ERN1 4276/4885HPGD 62/4885TSHR 2482/4885
US-12624022-B2 Heterocyclic immunomodulators as PDL1 checkpoint inhibitor CD274, PDCD1, PDCD1LG2 ERN1 2654/4885HPGD 2031/4885TSHR 311/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 ERN1 1934/4885HPGD 3944/4885TSHR 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.